$67.76
2.42% yesterday
NYSE, Nov 15, 10:00 pm CET
ISIN
US28176E1082
Symbol
EW

Edwards Lifesciences Stock price

$67.76
-1.14 1.65% 1M
-22.40 24.84% 6M
-8.49 11.13% YTD
+0.75 1.12% 1Y
-48.93 41.93% 3Y
-14.12 17.24% 5Y
+46.72 222.08% 10Y
NYSE, Closing price Fri, Nov 15 2024
+1.60 2.42%
ISIN
US28176E1082
Symbol
EW
Sector

Key metrics

Market capitalization $39.96b
Enterprise Value $36.29b
P/E (TTM) P/E ratio 9.77
EV/FCF (TTM) EV/FCF 70.39
EV/Sales (TTM) EV/Sales 6.18
P/S ratio (TTM) P/S ratio 6.81
P/B ratio (TTM) P/B ratio 4.19
Revenue growth (TTM) Revenue growth 0.92%
Revenue (TTM) Revenue $5.87b
EBIT (operating result TTM) EBIT $1.60b
Free Cash Flow (TTM) Free Cash Flow $515.50m
Cash position $4.45b
EPS (TTM) EPS $6.93
P/E forward 26.82
P/S forward 6.69
EV/Sales forward 6.06
Short interest 1.32%
Show more

Is Edwards Lifesciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Edwards Lifesciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a Edwards Lifesciences forecast:

14x Buy
42%
19x Hold
58%

Analyst Opinions

33 Analysts have issued a Edwards Lifesciences forecast:

Buy
42%
Hold
58%

Financial data from Edwards Lifesciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
5,873 5,873
1% 1%
100%
- Direct Costs 1,329 1,329
3% 3%
23%
4,544 4,544
2% 2%
77%
- Selling and Administrative Expenses 1,715 1,715
8% 8%
29%
- Research and Development Expense 1,081 1,081
5% 5%
18%
1,748 1,748
4% 4%
30%
- Depreciation and Amortization 149 149
9% 9%
3%
EBIT (Operating Income) EBIT 1,599 1,599
4% 4%
27%
Net Profit 4,159 4,159
191% 191%
71%

In millions USD.

Don't miss a Thing! We will send you all news about Edwards Lifesciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Edwards Lifesciences Stock News

Neutral
PRNewsWire
about 2 hours ago
LOS ANGELES , Nov. 15, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or the "Company") (NYSE: EW). Class Period: February 6, 2024 – July 24, 2024 Lead Plaintiff Deadline: December 13, 2024 If you wish to s...
Neutral
GlobeNewsWire
about 10 hours ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Edwards To Contact Him Directly To Discuss Their Options
Neutral
PRNewsWire
one day ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Edwards To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Edwards between February 6, 2024 and July 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292...
More Edwards Lifesciences News

Company Profile

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring system measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Head office United States
CEO Bernard Zovighian
Employees 19,800
Founded 1958
Website www.edwards.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today